ConductScience.org, home

Paper39697333

From promise to practice: CAR T and Treg cell therapies in autoimmunity and other immune-mediated diseases.

Bulliard Y and 6 others. Front Immunol, 2024. Cited by 34 papers, by iCite.

Cite this record

ConductScience Library. From promise to practice: CAR T and Treg cell therapies in autoimmunity and other immune-mediated diseases. Papers, record 39697333. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39697333

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
From promise to practice: CAR T and Treg cell therapies in autoimmunity and other immune-mediated diseases.
PubMed
Journal
Front Immunol
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
34
iCite
Relative citation ratio, by iCite
4.52, provisional
iCite
Revised in PubMed
2026-08-13
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Bulliard YYannick
2Freeborn RRobert
3Uyeda MJMolly Javier
4Humes DDaryl
5Bjordahl RRyan
6de Vries DDavid
7Roncarolo MGMaria Grazia

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
T-Lymphocytes, RegulatoryMajor topic
Autoimmune DiseasesMajor topic
Immunotherapy, AdoptiveMajor topic
AutoimmunityMajor topic
Receptors, Chimeric AntigenMajor topic
Humans
Animals

Source PubMed

Download CSV of topics

References228

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133855972Selective expansion of regulatory T cells using an orthogonal IL-2/IL-2 receptor system facilitates transplantation tolerance.J Clin Invest2021https://conductscience.org/library/papers/33855972PubMed
237481700Dual-locus, dual-HDR editing permits efficient generation of antigen-specific regulatory T cells with robust suppressive activity.Mol Ther2023https://conductscience.org/library/papers/37481700PubMed
329385370Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.N Engl J Med2018https://conductscience.org/library/papers/29385370PubMed
424321746Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients.Biol Blood Marrow Transplant2014https://conductscience.org/library/papers/24321746PubMed
539013470Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis.Cell2024https://conductscience.org/library/papers/39013470PubMed
628803861Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy.Mol Ther2017https://conductscience.org/library/papers/28803861PubMed
739231352Teclistamab-Induced Remission in Refractory Systemic Lupus Erythematosus.N Engl J Med2024https://conductscience.org/library/papers/39231352PubMed
837834955Mesenchymal Stem Cell Therapy in Multiple Sclerosis: A Systematic Review and Meta-Analysis.J Clin Med2023https://conductscience.org/library/papers/37834955PubMed
918824594
Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system.
Blood2009https://conductscience.org/library/papers/18824594PubMed
1029980618Revisiting IL-2: Biology and therapeutic prospects.Sci Immunol2018https://conductscience.org/library/papers/29980618PubMed
1137295445Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study.Lancet2023https://conductscience.org/library/papers/37295445PubMed
1238697115Treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR T cells.Neuron2024https://conductscience.org/library/papers/38697115PubMed
1332864635Therapeutic Targeting of Follicular T Cells with Chimeric Antigen Receptor-Expressing Natural Killer Cells.Cell Rep Med2020https://conductscience.org/library/papers/32864635PubMed
1422566933Molecular mechanisms of treg-mediated T cell suppression.Front Immunol2012https://conductscience.org/library/papers/22566933PubMed
1516203864Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells.J Exp Med2005https://conductscience.org/library/papers/16203864PubMed
1629593838B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets.Ther Adv Neurol Disord2018https://conductscience.org/library/papers/29593838PubMed
1731443677Mesenchymal stem cells for the treatment of ulcerative colitis: a systematic review and meta-analysis of experimental and clinical studies.Stem Cell Res Ther2019https://conductscience.org/library/papers/31443677PubMed
1839874224CD19-CAR T-cell therapy induces deep tissue depletion of B cells.Ann Rheum Dis2025https://conductscience.org/library/papers/39874224PubMed
199180086HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia.Science1997https://conductscience.org/library/papers/9180086PubMed
2031900462'Off-the-shelf' allogeneic CAR T cells: development and challenges.Nat Rev Drug Discov2020https://conductscience.org/library/papers/31900462PubMed

See all 228 referencesDownload CSV of references

Cited by26

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 34 citations.

PMIDTitleJournalYearIn PapersSource
42812913Immunotherapy of membranous nephropathy: strategic evolution from CD20 monoclonal antibodies to future vaccines.Front Immunol2026https://conductscience.org/library/papers/42812913PubMed
42756163Emerging CAR-Treg and regulatory T cell therapies for inflammatory bowel diseases: a systematic review of a new era of treatment.Front Immunol2026https://conductscience.org/library/papers/42756163PubMed
42656618CAR-T cells and CAR-Treg cells for treatment of inflammatory bowel diseases.EULAR Rheumatol Open2026https://conductscience.org/library/papers/42656618PubMed
42645190Regulatory T Cell (Treg): Central Orchestrator of Immune Homeostasis.Cells2026https://conductscience.org/library/papers/42645190PubMed
42548760Immunological heterogeneity in rheumatoid arthritis: challenges in early-stage stratification, non-response to targeted therapy, and the restoration of immune tolerance.Front Immunol2026https://conductscience.org/library/papers/42548760PubMed
42539630Emerging immune networks and targeted strategies in T2 asthma.Front Immunol2026https://conductscience.org/library/papers/42539630PubMed
42495646Engineering allogeneic type 1 regulatory T cells: a scalable, off-the-shelf platform for restoring immune tolerance.Front Immunol2026https://conductscience.org/library/papers/42495646PubMed
42491551Advancements in multiple myeloma treatment: Integrating quadruplet and dual antigen CAR-T therapy.iScience2026https://conductscience.org/library/papers/42491551PubMed
42380621Engineering immune cell therapies for inflammatory bowel disease: from stem cells to CAR T cells.Nat Rev Gastroenterol Hepatol2026https://conductscience.org/library/papers/42380621PubMed
42191896T cell-targeted immunotherapies for multiple sclerosis: molecular mechanisms to therapeutic perspectives from Traditional Chinese medicine.Acta Pharmacol Sin2026https://conductscience.org/library/papers/42191896PubMed
41953032Advancements and expanding applications of CAR-T cell therapy.Front Immunol2026https://conductscience.org/library/papers/41953032PubMed
41878448Miniaturized IL-2/anti-IL-2 immunocytokines selectively activate and support the in vivo persistence of regulatory T cells.Front Immunol2026https://conductscience.org/library/papers/41878448PubMed
41756305Beyond cytokine blockade: could CAR-Tregs open a new era of tissue-targeted immune tolerance in psoriatic arthritis?Front Immunol2026https://conductscience.org/library/papers/41756305PubMed
41751878In Vivo CAR-T Therapies-A New Era of Programmable Immunity.Int J Mol Sci2026https://conductscience.org/library/papers/41751878PubMed
41607801The immunobiology and therapeutic potential of regulatory T cells in autoimmune diseases and allergic diseases.Front Immunol2025https://conductscience.org/library/papers/41607801PubMed
41596556Engineering Immunity: Current Progress and Future Directions of CAR-T Cell Therapy.Int J Mol Sci2026https://conductscience.org/library/papers/41596556PubMed
41522472Organ Transplantation: Current Status, Challenges, and Future Prospects.MedComm (2020)2026https://conductscience.org/library/papers/41522472PubMed
41373685The Potential of β-Synuclein-Specific Regulatory T Cell Therapy as a Treatment for Progressive Multiple Sclerosis.Int J Mol Sci2025https://conductscience.org/library/papers/41373685PubMed
41368361Cellular therapy in neuromyelitis optica spectrum disorder.Front Neurol2025https://conductscience.org/library/papers/41368361PubMed
41315911CAR T cell therapy in type 1 diabetes: what we know and what remains to be explored.Biol Proced Online2025https://conductscience.org/library/papers/41315911PubMed

See all 26 cited byDownload CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD19930PubTator's text mininghttps://conductscience.org/library/genes/930NCBI Gene
FOXP350943PubTator's text mininghttps://conductscience.org/library/genes/50943NCBI Gene
NR1I39970PubTator's text mininghttps://conductscience.org/library/genes/9970NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39697333

GET https://conductscience.org/api/papers/v1/39697333/references?page=2